Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin icodec - Novo Nordisk

Next Previous
Drug Profile

Insulin icodec - Novo Nordisk

Alternative Names: 148-0287-A; AWIQLI; Insulin 287; Insulin icodec-abae; LAI-287; Long-acting basal insulin analogue-287 - Novo-Nordisk; Long-acting-insulin-287 - Novo-Nordisk; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI 287GT

Latest Information Update: 09 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 27 Mar 2026 Registered for Type 2 diabetes mellitus in USA (SC)
  • 27 Mar 2026 Novo Nordisk plans to launch Insulin icodec for Type 2 diabetes mellitus in 2H of 2026
  • 29 Sep 2025 Novo Nordisk resubmits its Biologics License Application (BLA) to the US FDA for Awiqli® (insulin icodec) for Type 2 diabetes

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top